Envestnet Asset Management Inc. Has $32.30 Million Stock Position in Medpace Holdings, Inc. $MEDP

Envestnet Asset Management Inc. grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 9.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 102,904 shares of the company’s stock after purchasing an additional 9,118 shares during the quarter. Envestnet Asset Management Inc. owned about 0.37% of Medpace worth $32,298,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Invesco Ltd. lifted its holdings in Medpace by 9.4% during the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock worth $361,596,000 after acquiring an additional 102,015 shares in the last quarter. Mawer Investment Management Ltd. bought a new position in Medpace during the first quarter worth about $212,131,000. AQR Capital Management LLC lifted its holdings in Medpace by 12.4% during the first quarter. AQR Capital Management LLC now owns 539,547 shares of the company’s stock worth $158,470,000 after acquiring an additional 59,361 shares in the last quarter. TD Asset Management Inc lifted its holdings in Medpace by 15.6% during the second quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock worth $143,636,000 after acquiring an additional 61,764 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in Medpace by 36.0% during the first quarter. Northern Trust Corp now owns 337,489 shares of the company’s stock worth $102,830,000 after acquiring an additional 89,347 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Up 0.8%

Shares of NASDAQ MEDP opened at $584.91 on Monday. The business’s 50 day moving average price is $515.52 and its two-hundred day moving average price is $403.46. The company has a market cap of $16.48 billion, a PE ratio of 40.90, a price-to-earnings-growth ratio of 2.67 and a beta of 1.40. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $625.00.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. During the same quarter in the previous year, the business earned $3.01 earnings per share. The business’s revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on MEDP. Truist Financial set a $555.00 target price on Medpace in a report on Monday, October 27th. TD Cowen boosted their price target on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a report on Friday, October 24th. Jefferies Financial Group lifted their target price on Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research report on Tuesday, September 9th. Mizuho lifted their target price on Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research report on Friday, October 24th. Finally, Robert W. Baird set a $613.00 target price on Medpace in a research report on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, nine have issued a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $475.90.

Insider Buying and Selling

In other news, General Counsel Stephen P. Ewald sold 15,230 shares of the company’s stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $598.85, for a total value of $9,120,485.50. Following the transaction, the general counsel owned 13,343 shares of the company’s stock, valued at approximately $7,990,455.55. This represents a 53.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO August J. Troendle sold 36,196 shares of the business’s stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $475.90, for a total value of $17,225,676.40. Following the completion of the sale, the chief executive officer owned 925,799 shares of the company’s stock, valued at approximately $440,587,744.10. This trade represents a 3.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 88,736 shares of company stock valued at $47,286,494 in the last ninety days. 20.30% of the stock is currently owned by company insiders.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.